Health tech firm Hyperfine prelim Q4 revenue rises 127% on Swoop system adoption

Hyperfine

12/01/2026 13:25

Overview

Health tech firm's preliminary Q4 revenue rises 127% yr/yr, driven by Swoop system adoption

Preliminary Q4 net cash burn down 30% yr/yr

Company exits 2025 with approximately $35 mln in cash and equivalents

Outlook

Hyperfine to provide full 2025 results and 2026 outlook in March 2026 earnings call

Result Drivers

REVENUE GROWTH - Hyperfine's Q4 revenue increased 127% yr/yr, driven by Swoop system adoption in hospitals, neurology offices, and international markets

TECHNOLOGY LAUNCHES - Recent launches of next-gen Swoop System and Optive AI software contributed to Q4 growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Beat
$5.30 mln
$5.005 mln (2 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Hyperfine Inc is $1.65, about 63.4% above its January 9 closing price of $1.01

Press Release: ID:nBw5zSfsSa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)